Live Breaking News & Updates on Uc san diego moore cancer center

Stay updated with breaking news from Uc san diego moore cancer center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

NCOIL adopts two new health insurance model laws

NCOIL adopts two new health insurance model laws
insurancenewsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insurancenewsnet.com Daily Mail and Mail on Sunday newspapers.

United-states , Kentucky , Minneapolis , Minnesota , New-york , West-virginia , Arkansas , Texas , America , American , Americans , Deborah-ferguson

Integrating EMR Systems Across Departments Improves Care in Brachytherapy Suite

Integrating electronic medical records systems across departments allowed for consistent and continuous sharing of patients’ care plans and information.

California , United-states , San-diego , Zachary-peterson , Radiation-oncology-brachytherapy-team , Uc-san-diego-health-cancer-services , Oncology-nursing-society , San-diego-health-center , University-of-california , Uc-san-diego-moore-cancer-center , San-diego-health , Annual-oncology-nursing-society

NEUVOGEN Appoints Cellular Immune Therapy Expert, Dr. Jack Bui to its Scientific Advisory Board

NEUVOGEN Appoints Cellular Immune Therapy Expert, Dr. Jack Bui to its Scientific Advisory Board
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

California , United-states , San-diego , Robert-schreiber , Todd-binder , Steve-hedrick , Jack-bui , University-of-california , Neuvogen-inc , Department-of-pathology , San-diego-stem-cell-processing-laboratory , Immunology-laboratory

Zymergen Provides Business Update

Zymergen Provides Business Update
Zymergen Inc.
Jay Flatley, Chairman of the Board, Appointed Acting CEO; Josh Hoffman to Step Down
Conference Call to be Held at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Today
EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today provided a business update regarding its commercial product pipeline and financial forecast.
Zymergen recently became aware of issues with its commercial product pipeline that will impact the Company’s delivery timeline and revenue projections. Accordingly, the Company no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.
During the quarter, several key target customers encountered technical issues in implementing Hyaline into their manufacturing processes typical of new product and process development learnings. The Company has made significant progress towards addressing these challenges and believes there are no intrinsic technical issues with Hyaline. However, this issue has resulted in a delay in the Company’s commercial ramp. Zymergen is working to strengthen its commercial team to ensure the reliability and robustness of the sales pipeline qualification and forecast processes.

Sandi-peterson , Jay-flatley , Mike-dulin , Josh-hoffman , Niraj-javeri , Board-of-trustees , Company-board-of-directors , Claremont-mckenna-college , Exchange-commission , Company-form , Strategic-oversight-committee , Boards-of-denali-therapeutics-inc